Melanotan I (Afamelanotide): The Approved MC1R Agonist Behind Scenesse

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to afamelanotide (Scenesse). This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Most people who search for "Melanotan 1" are thinking about cosmetic tanning. What they find, if they look carefully, is a more complicated story: a compound with a legitimate FDA-approved medical use, a distinct pharmacological profile from the unregulated "Melanotan 2" circulating online, and a body of clinical evidence that has very little to do with sunless tanning. The compound has been approved in the United States since 2019 for a rare inherited disorder that turns sunlight into a source of severe, disabling pain. Understanding what it actually is changes the entire conversation.

This article covers afamelanotide, the compound commercially known as Scenesse: its origin, how it selectively activates the MC1R melanocortin receptor, what the Phase 3 clinical trial data showed for erythropoietic protoporphyria (EPP), what early research suggests about vitiligo, and why it is fundamentally different from Melanotan II in both mechanism and risk profile.

Key Takeaways

• Regulatory Status: Afamelanotide (brand: Scenesse) is an FDA-approved prescription drug as of October 2019, indicated for adults with erythropoietic protoporphyria (EPP) to increase pain-free sun exposure. The European Medicines Agency approved it in 2014. As of April 2026, no indication exists for cosmetic tanning.
• Research Stage: Landmark Phase 3 RCT published in the New England Journal of Medicine in 2015; substantial post-approval real-world effectiveness data available.
• Availability: FDA-approved prescription-only subcutaneous implant. Available only through licensed prescribers in the US for the approved EPP indication. Superpower does not offer this medication.
• What it is: A synthetic, protease-resistant analog of alpha-melanocyte-stimulating hormone (α-MSH) that selectively binds the MC1R receptor to stimulate eumelanin production and photoprotection.
• What the evidence actually shows: In the 2015 pivotal RCT by Langendonk and colleagues, EPP patients receiving afamelanotide tolerated significantly more direct sun exposure and reported meaningfully better quality of life versus placebo. Reference: Langendonk et al., published in the New England Journal of Medicine in 2015.
• Prescribing information: PubChem CID 2656580

Where Afamelanotide Comes From and How It Works

Origin and discovery

Afamelanotide was not synthesized to create a tanning agent. It was developed in the early 1980s by Victor Hruby and Mac Hadley's group at the University of Arizona as a stable research tool for studying melanotropin biology. The natural hormone alpha-melanocyte-stimulating hormone (α-MSH) degrades rapidly in vivo and was difficult to study in controlled conditions. In a foundational 1980 paper published in the Proceedings of the National Academy of Sciences, Sawyer and colleagues in the Hadley group described a synthetic analog with two substitutions at positions 4 and 7 of the α-MSH sequence — a norleucine replacing methionine at position 4, and a D-phenylalanine replacing L-phenylalanine at position 7. These changes produced a compound with substantially longer biological activity and resistance to enzymatic degradation. That compound, designated [Nle4, D-Phe7]-α-MSH, became what is now known as afamelanotide, and later Melanotan I.

MC1R selectivity: the defining pharmacological feature

The melanocortin receptor family comprises five subtypes — MC1R through MC5R — distributed across different tissues and mediating different effects. MC1R is expressed primarily on melanocytes (the pigment-producing cells in skin and hair follicles), where it controls eumelanin versus pheomelanin synthesis. MC3R and MC4R are expressed centrally and peripherally, with MC4R playing a major role in appetite regulation and sexual function. MC2R is the primary ACTH receptor in the adrenal cortex.

Afamelanotide's clinical importance derives partly from its preferential engagement of MC1R relative to the other subtypes. A 2023 pharmacology review by Mun, Kim, and Shin, published in the International Journal of Molecular Sciences, described MC1R's signaling cascade in detail: MC1R activation triggers adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and activates the MITF (microphthalmia-associated transcription factor) pathway, which drives expression of tyrosinase and related enzymes involved in eumelanin synthesis. Guida and colleagues, writing in the Journal of Investigative Dermatology in 2022, extended this picture by documenting that MC1R activation also upregulates nucleotide excision repair enzymes and antioxidant pathways, suggesting the receptor has photoprotective functions beyond pigmentation alone. This has direct relevance for EPP: eumelanin absorbs and dissipates phototoxic energy that would otherwise reach the porphyrins accumulating in EPP patients' blood vessels.

Why MC1R selectivity distinguishes afamelanotide from Melanotan II

Melanotan II — a cyclic, truncated analog developed separately — binds MC1R, MC3R, MC4R, and MC5R with much less selectivity than afamelanotide. The broader receptor activity produces a different adverse effect profile. In a 1996 Phase I study by Dorr and colleagues, published in Life Sciences, Melanotan II produced tanning alongside dose-dependent nausea, flushing, and spontaneous erections — effects consistent with central MC4R activation, not MC1R activation. Those findings explain why Melanotan II has not progressed to approved drug status: the MC4R-driven side effects are difficult to separate from any tanning benefit. Afamelanotide's more selective receptor engagement allows the EPP indication to proceed without those off-target neurological and gastrointestinal effects. This comparison is for scientific context only. These compounds have fundamentally different regulatory statuses and evidence bases, and the MC4R-mediated effects of Melanotan II are among the reasons it remains unapproved and carries substantial unregulated-use risks.

Erythropoietic Protoporphyria: The Disease Behind the Approval

What EPP is and why sunlight causes pain

Erythropoietic protoporphyria is a rare inherited metabolic disorder caused by deficient activity of ferrochelatase, the terminal enzyme in heme biosynthesis. Ferrochelatase catalyzes the insertion of iron into protoporphyrin IX to form heme. When this enzyme is deficient, protoporphyrin IX accumulates in red blood cells, plasma, and skin. A comprehensive 2025 review by Minder and colleagues, published in Liver International, describes EPP pathogenesis and management in full: when protoporphyrin-laden erythrocytes circulate through superficial cutaneous vessels, visible and near-UV light activates the porphyrin to a singlet oxygen excited state, triggering a phototoxic cascade that causes severe burning pain, erythema, and edema within minutes to hours of sun exposure. Unlike classic porphyrias, EPP-associated photosensitivity produces immediate pain without blistering — a presentation that is often dismissed or misdiagnosed for years. Evidence-based consensus guidelines for EPP diagnosis and management, published in the Journal of the American Academy of Dermatology in 2023 by Dickey and colleagues, recommend afamelanotide as a primary pharmacological intervention for adults with EPP-related photosensitivity.

How afamelanotide addresses the underlying mechanism

Afamelanotide does not reduce protoporphyrin accumulation and does not address the ferrochelatase deficiency. Its mechanism of action in EPP is purely photoprotective: by stimulating MC1R on melanocytes, it drives eumelanin production in skin before the patient is exposed to light. Eumelanin has a broad UV and visible light absorption spectrum and physically dissipates phototoxic energy as heat before it can reach porphyrin-bearing vessels. In a 2006 controlled human skin study published in the Journal of Investigative Dermatology, Barnetson, Ooi, and colleagues enrolled 65 fair-skinned Caucasian volunteers and showed that [Nle4, D-Phe7]-α-MSH (afamelanotide) increased epidermal melanin density by roughly 41% and reduced UV-induced thymine-dimer DNA damage in the basal epidermis by approximately 59%, providing the mechanistic human-skin data linking MC1R activation to photoprotection. The clinical implication for EPP is that a higher melanin baseline in skin increases the threshold of light exposure that can be tolerated before phototoxic pain begins — extending the window of outdoor activity available to patients whose condition otherwise restricts them severely.

What the Clinical Evidence Shows

The pivotal Phase 3 RCT

The evidentiary foundation for afamelanotide's FDA approval is two parallel double-blind, placebo-controlled Phase 3 trials reported together by Langendonk, Balwani, Anderson, Bonkovsky, and colleagues in the New England Journal of Medicine in 2015. The companion US and EU studies randomized a combined 168 adults with EPP (93 US, 74 EU) to 16 mg afamelanotide as a subcutaneous bioresorbable implant (administered every 60 days for 180 days in the US trial and every 60 days for 270 days in the EU trial) or matching placebo. The primary outcome was time spent in direct sunlight without pain. In the US trial, the afamelanotide group accumulated a median 69.4 pain-free hours in direct sunlight versus 40.8 hours in the placebo group (p = 0.04); in the EU trial, the afamelanotide group accumulated a median 6.0 versus 0.8 pain-free hours in direct sunlight between 10:00 and 18:00 (p = 0.005) and experienced fewer phototoxic reactions (77 vs. 146, p = 0.04), with parallel improvements in disease-specific quality-of-life measures. Adverse events were predominantly implant-site reactions and nausea, with no serious drug-related toxicities reported. This trial, registered as CUV029/CUV039, was the pivotal study reviewed by both the FDA and EMA in their respective approvals.

European observational and real-world effectiveness data

A large European observational study by Biolcati and colleagues, published in the British Journal of Dermatology in 2015, followed 115 EPP patients across porphyria centers in Rome and Zurich who received repeated 16 mg afamelanotide implants over up to 8 years, with EPP-specific quality-of-life scores rising from 31 ± 24% of maximum before treatment to 74% after initiation and remaining at that level across the observation period; adverse events were minor and predominantly nausea, though 23% discontinued for reasons including pregnancy and cost, which limits interpretation of long-term persistence. Post-approval cohort data continued to accumulate. A 2020 prospective postauthorization cohort study by Wensink and colleagues, published in JAMA Dermatology, followed 117 EPP patients (59 women; mean age 43.0 years) over a median 2.0 years (IQR 1.3–2.1) and found a mean increase in weekly time spent outdoors of 6.1 hours (95% CI 3.62–8.67; p < 0.001) and a 14.01% improvement in EPP-specific quality of life (95% CI 4.53%–23.50%; p < 0.001), with a 98% treatment-continuation rate and minor adverse events limited to nausea, fatigue, and headache. A 2020 three-year observational study by Barman-Aksözen and colleagues, published in the Orphanet Journal of Rare Diseases, followed 39 Swiss EPP patients from 2016 to 2018 and documented that median phototoxic burn tolerance time rose from 10 minutes (IQR 5–20) before treatment to 180 minutes (IQR 120–240) during treatment, maximum pain on a visual analogue scale fell from a median of 10 to 6 (IQR 3–7), and EPP-specific quality of life reached 81.4% (IQR 69.4–93.4) by study end; PBTT correlated inversely with time since last implant (Kendall's τ = −0.382, p < 0.0001), with treatment adherence of 97.4% — the small single-country cohort limits generalizability but provides rare durability evidence. A 2023 retrospective cohort by Ceresnie and colleagues, published in the Journal of the American Academy of Dermatology, reported US practice data on afamelanotide in adults with EPP and X-linked protoporphyria, adding North-American real-world experience alongside the European registries; the PubMed record does not post an abstract, so per-group effect sizes are not surfaced here and readers should consult the full text for quantitative detail. A 2023 Netherlands cohort by Wensink and colleagues, published in the Journal of Dermatology, described the psychosocial burden of EPP and the effect of afamelanotide on both phototoxic tolerance and psychological wellbeing, providing the disease-burden context that makes the functional improvement data interpretable.

The pharmacokinetics of the implant formulation

Afamelanotide is not administered as an injectable solution. The 16 mg dose is delivered as a rod-shaped, bioresorbable poly(D,L-lactide-co-glycolide) implant placed subcutaneously (typically in the lower abdomen or flank) by a trained clinician. The implant releases the peptide in a controlled manner over approximately 60 days, producing a sustained pharmacokinetic profile. A 2016 drug review by Kim and Garnock-Jones, published in the American Journal of Clinical Dermatology, summarized the pharmacokinetics of the 16 mg controlled-release implant: peak plasma concentrations are reached within 24 to 72 hours of insertion, and the extended-release profile is specifically designed to maintain melanocyte stimulation for weeks rather than delivering a bolus dose that would produce acute off-target effects. This delivery mechanism — designed and approved for a clinical indication — is categorically different from injectable powders available through unregulated online vendors.

Vitiligo Research: Off-Label Investigation

The rationale for exploring MC1R agonism in vitiligo

Vitiligo is a depigmenting condition in which autoimmune destruction of melanocytes produces patches of skin lacking melanin. The conventional first-line approach is narrowband ultraviolet-B (NB-UVB) phototherapy, which can stimulate repigmentation from melanocyte reservoirs in hair follicles and perilesional skin. The hypothesis behind afamelanotide in vitiligo is that augmenting MC1R signaling alongside NB-UVB could prime remaining melanocytes to respond more robustly to phototherapy, accelerating and extending repigmentation. This is not a simple tanning application: it is the use of a melanocyte-activating signal to potentiate a validated phototherapy protocol in a specific disease context.

Early clinical trial findings

A small 2013 proof-of-concept case series by Grimes, Hamzavi, Lebwohl, and Ortonne, published in JAMA Dermatology, reported on 4 patients with generalized vitiligo who received 16 mg afamelanotide implants monthly for four months alongside narrowband UV-B phototherapy three times weekly and showed follicular and confluent repigmentation in all four patients within 2 days to 4 weeks of the first implant, though the very small, uncontrolled cohort limits the strength of this signal. A subsequent randomized multicenter trial by Lim, Grimes, and colleagues, published in JAMA Dermatology in 2015, enrolled 55 patients with generalized vitiligo across three US sites and randomized them to combined afamelanotide (16 mg implants monthly × four) plus NB-UVB (n = 28) or NB-UVB alone (n = 27); at day 168, the combination group achieved 48.6% repigmentation versus 33.3% with NB-UVB alone (95% CIs 39.5–57.8% vs. 24.2–42.3%), with faster median time to facial repigmentation (41 vs. 61 days, p = 0.001) and upper-extremity repigmentation (46 vs. 69 days, p = 0.003), and the largest effects observed in patients with Fitzpatrick skin types IV–VI. A 2020 study by Toh and colleagues, published in the Journal of the American Academy of Dermatology, extended these findings to Asian patients with nonsegmental vitiligo and skin types IV-V, confirming efficacy and tolerability of the combination approach in a higher skin-type population. As of April 2026, afamelanotide is not FDA-approved for vitiligo. This research is ongoing and represents an off-label investigational use for an approved compound. Prescribing decisions for off-label use represent the independent clinical judgment of licensed providers.

Afamelanotide vs. Melanotan II: Key Differences

These compounds are frequently conflated online despite being meaningfully different in structure, receptor selectivity, regulatory status, and risk profile. Understanding the distinction matters because the evidence for one does not apply to the other.

Afamelanotide (Melanotan I) is a linear 13-amino-acid peptide with an open-chain structure. It binds MC1R with high relative affinity compared to other melanocortin receptor subtypes, producing its primary effect on skin melanocytes with limited central nervous system activity at approved doses. It is FDA-approved, available only by prescription for a specific indication, delivered through a precisely manufactured controlled-release implant, and manufactured to pharmaceutical standards.

Melanotan II is a cyclic 7-amino-acid analog with a different structural core. It binds MC1R, MC3R, MC4R, and MC5R without the selectivity that characterizes afamelanotide. As noted in the 1996 Dorr et al. Phase I data referenced above, MC4R activation produces nausea, facial flushing, and spontaneous erections — effects that drove the side effect burden in early human studies. Melanotan II has not received FDA approval or EMA approval for any indication. It is not legally marketed for human use in the United States. Products sold online as injectable Melanotan II are not manufactured to pharmaceutical standards, are not subject to FDA oversight, and have no approved route of administration.

A 2017 review by Habbema and colleagues, published in the International Journal of Dermatology, specifically examined risks from unregulated use of α-MSH analogs including both Melanotan I and Melanotan II, documenting injection-site reactions, gastrointestinal effects, and pigmentary changes in moles and nevi that have been reported with uncontrolled use. A 2022 observational analysis by Hadeler, Haitz, and Bray, published in the Journal of the American Academy of Dermatology, examined online-purchased α-MSH analogs and found frequent compound misidentification, contamination, and purity problems in products marketed for self-injection. These are not theoretical risks: injectable products sold outside of a pharmaceutical supply chain carry real hazards that the clinical data from Scenesse cannot be applied to. This comparison is for scientific context only. These compounds have fundamentally different regulatory statuses and evidence bases.

Safety: What Is and Is Not Known

Adverse effects in clinical trials

The safety profile of afamelanotide in clinical trials and post-approval surveillance is documented most thoroughly in a 2021 focused review by Wensink and colleagues, published in Expert Review of Clinical Pharmacology, covering mechanism, clinical data, implant-site reactions, and monitoring recommendations. The most commonly reported adverse effects are related to the implant procedure itself: injection-site bruising, transient erythema, and hematoma at the implantation site are the most frequent findings. Nausea is reported in a subset of patients, particularly in the days following implant insertion, and generally resolves without intervention. Pigmented nevi (moles) may darken during afamelanotide treatment due to systemic MC1R stimulation; clinical guidance recommends monitoring any existing nevi and reporting new or changing lesions to a dermatologist. Hyperpigmentation at the implant site has been reported. As of April 2026, no serious organ toxicities attributable to afamelanotide have been identified in the approved clinical trial and post-market data.

Melanoma monitoring and the nevi question

MC1R variants are associated with increased melanoma susceptibility, and any compound that broadly stimulates MC1R raises the theoretical question of whether it could affect melanocyte proliferation. The clinical trial data from Scenesse do not demonstrate an increased incidence of melanoma. Nevertheless, dermatological monitoring for new or changing pigmented lesions during treatment is recommended as a standard clinical precaution. Patients with a personal or family history of melanoma, or with atypical mole syndrome, require particularly careful evaluation before initiating therapy.

Risks from unregulated sources

Any injectable product labeled "Melanotan I" sold through online vendors, research chemical suppliers, or unregulated international pharmacies is not the pharmaceutical-grade afamelanotide used in clinical trials. It is not subject to FDA manufacturing standards, is not tested for sterility or correct dosing, and may contain contaminants or entirely different compounds. The Hadeler et al. 2022 analysis referenced above confirmed these quality problems in practice. There is no legal or safe pathway to obtain pharmaceutical-grade afamelanotide for cosmetic use in the United States. Scenesse is a prescription-only product dispensed through licensed specialty pharmacies for patients with confirmed EPP under a prescribing physician's care.

Who Should Not Use Afamelanotide

Prescribers evaluate individual risk factors before initiating Scenesse. Based on the compound's approved labeling and proposed mechanism, the following populations require particular clinical scrutiny or represent contraindications:

• Individuals with a personal history of melanoma or other skin malignancies — MC1R activation broadly stimulates melanocytes, and any potential proliferative signal in a patient with existing melanocyte pathology requires careful individual risk assessment
• Individuals with atypical mole syndrome or a high baseline nevus burden — nevi darkening during treatment can complicate dermatological surveillance and warrants dermatologist-led monitoring before and during use
• Patients with severe renal or hepatic impairment — pharmacokinetic data in these populations are limited; clearance may be altered
• Pregnant individuals — no adequate safety data exist in human pregnancy; the risk-benefit evaluation is the prescriber's clinical judgment
• Children and adolescents — Scenesse is approved only in adults; pediatric pharmacokinetic and safety data are not available
• Individuals seeking cosmetic tanning — afamelanotide has no approved cosmetic indication; using it outside of the EPP indication represents off-label use and removes the protections of the approved indication's clinical monitoring framework

Which Biomarkers Are Relevant if You Are Exploring Photosensitivity or Inflammatory Skin Conditions?

For people interested in skin health, photosensitivity, or inflammatory dermatological conditions, objective biomarker data provides important biological context — regardless of which interventions are ultimately discussed with a clinician.

• High-sensitivity CRP (hs-CRP): Systemic low-grade inflammation is a driver of multiple dermatological conditions and can confound the interpretation of photosensitivity symptoms. hs-CRP is the most sensitive blood marker for low-grade systemic inflammation and provides baseline context for anyone evaluating skin or immune system reactivity. Understanding inflammatory markers is a reasonable starting point for any photosensitivity workup.
• Ferritin: In EPP, the underlying pathology involves deficient heme synthesis, and iron status is relevant to the heme metabolic pathway. Ferritin is the most sensitive available marker for iron stores and provides context for heme synthesis capacity. Low iron stores can also contribute to fatigue and symptoms that overlap with other conditions relevant to light sensitivity.
• Complete blood count (CBC): EPP and related porphyrias affect erythrocyte function. A complete blood count establishes the baseline red cell picture, including hemoglobin and hematocrit, which are relevant to the heme metabolism context underlying EPP. Abnormalities in red cell indices can direct further workup.
• Liver function tests (ALT, AST, bilirubin): EPP is associated with hepatic porphyrin accumulation in a subset of patients, and liver involvement is a serious complication of advanced disease. Liver function biomarkers including ALT, AST, and bilirubin provide baseline context for anyone with known or suspected porphyria and are part of routine monitoring in EPP management.
• Vitamin D: Individuals with severe photosensitivity — including those with EPP — may restrict sun exposure to the point of developing vitamin D deficiency, since cutaneous vitamin D synthesis requires UV-B exposure. 25-hydroxyvitamin D provides objective data on this common secondary consequence of photosensitivity-driven sun avoidance.
• Immune system biomarkers: In vitiligo and other depigmenting conditions with an autoimmune driver, broader immune system assessment is relevant clinical context. Understanding immune system strength markers establishes the immunological baseline that dermatologists evaluate alongside pigmentation changes.

When to Take This Seriously

If severe, immediate pain with sun exposure has been a lifelong feature of your experience, that is not a normal sunburn response and warrants evaluation by a specialist in porphyria or a dermatologist with experience in photodermatoses. EPP is significantly underdiagnosed, and many patients carry a misdiagnosis for years before a correct diagnosis is established. The Dickey et al. 2023 consensus guidelines referenced above provide a diagnostic framework that begins with plasma fluorescence spectroscopy and erythrocyte protoporphyrin measurement — tests that can be ordered by informed clinicians. If you are managing existing vitiligo and interested in emerging approaches that combine NB-UVB with adjunctive agents, that conversation belongs with a dermatologist who can evaluate your skin type, disease distribution, and current treatment response. For anyone with photosensitivity, fatigue, or skin changes, understanding your objective biomarker picture, including iron stores, vitamin D, and inflammatory markers, provides the data that makes a clinical conversation more productive.

That principle of arriving at clinical decisions with objective data rather than symptoms alone is central to Superpower's approach to preventive health: understanding your baseline biology is the foundation for every health decision, whether you are navigating a rare disease, an autoimmune skin condition, or simply trying to make sense of what your body is telling you.

IMPORTANT SAFETY INFORMATION

Afamelanotide (Scenesse) is an FDA-approved prescription medication indicated for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It is approved only for this indication; there is no approved cosmetic tanning indication. Superpower Health does not prescribe, sell, or facilitate access to afamelanotide (Scenesse). This educational content does not constitute medical advice and does not represent a clinical recommendation. All prescribing decisions are the independent clinical judgment of a licensed provider.

Administration: Afamelanotide (Scenesse) is administered as a 16 mg subcutaneous bioresorbable implant by a trained clinician, typically every 60 days during the period of increased sun exposure risk. It is not an injectable solution, oral tablet, or nasal spray. Products sold online as injectable or reconstitutable "Melanotan 1" powder are not the approved Scenesse product and have no approved route of administration.

Warnings: Nevi (moles) may darken during treatment; dermatological monitoring of existing pigmented lesions is recommended. Any new or changing pigmented skin lesion during treatment should be evaluated by a dermatologist promptly. Implant-site reactions including bruising, erythema, and hematoma have been reported. Nausea has been reported, particularly in the days following implant insertion.

Contraindications and populations requiring additional clinical evaluation: personal history of melanoma or other skin malignancy; atypical mole syndrome or high nevus burden; severe renal or hepatic impairment; pregnancy (no adequate human safety data); pediatric patients (approved for adults only); individuals without a confirmed EPP diagnosis.

Common side effects: implant-site bruising, erythema, or hematoma; nausea; nevi darkening; hyperpigmentation at implant site.

Long-term safety: Post-approval surveillance data support the safety profile established in clinical trials for the EPP indication. Long-term safety beyond the approved indication has not been systematically studied.

Unregulated products: Injectable alpha-MSH analogs sold online are not FDA-regulated, have not been tested for purity or correct dosing, and carry contamination risks documented in independent testing. The clinical evidence for Scenesse does not apply to unregulated products.

Full FDA-approved prescribing information available at dailymed.nlm.nih.gov.

Additional Questions

What does afamelanotide do to moles and nevi?

Afamelanotide stimulates MC1R broadly on melanocytes throughout the skin, which can cause existing pigmented nevi (moles) to darken during treatment. This is a recognized effect and is why clinical monitoring of nevi is a standard recommendation during Scenesse therapy. Patients with a high nevus burden, atypical moles, or a personal or family history of melanoma require dermatological evaluation before and during treatment. Any new or changing pigmented lesion during treatment should be assessed by a dermatologist promptly.

Is afamelanotide being researched for vitiligo?

Yes, as an off-label investigational use. Multiple published trials have examined afamelanotide in combination with narrowband UV-B phototherapy for vitiligo repigmentation. The 2015 randomized multicenter trial by Lim and colleagues found that the combination produced superior repigmentation compared to NB-UVB alone, with the largest effects in patients with higher Fitzpatrick skin types. As of April 2026, afamelanotide is not FDA-approved for vitiligo. This is an area of active research, and any vitiligo treatment decisions should be made with a dermatologist.

Are peptides legal again after the 2026 FDA reclassification?

The February 2026 FDA reclassification affected compounded drugs using bulk drug substances, particularly peptides that had been listed as Category 2 (prohibited) under Section 503A. Afamelanotide (Scenesse) is not a compounded drug — it is an FDA-approved prescription product manufactured under an approved NDA and distributed through licensed pharmaceutical channels. Its legal status was not affected by the bulk drug substance reclassification. The reclassification is relevant to compounded peptides like BPC-157 and TB-500; it does not change the prescribing pathway for Scenesse.